CTOs on the Move

CODA Biotherapeutics

www.codabiotherapeutics.com

 
CODA Biotherapeutics` revolutionary chemogenetic platform aims to control the activity of cells to treat disease. With chemogenetics, the goal is to modify a target cell population using gene therapy to express a tunable `switch` protein. Cells modified with the `switch` can be activated or inactivated in a dose-dependent manner by a subsequently administered small molecule therapeutic, an effect that should only occur in the modified cells.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

CODA Biotherapeutics raised $19M on 10/03/2018
CODA Biotherapeutics raised $15M on 11/05/2019

Similar Companies

Dharmacon Research

Dharmacon Research is a Lafayette, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Du Pont Pharmaceuticals Co

Du Pont Pharmaceuticals Co is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Finishing Touch Salon

Finishing Touch Salon is a Waterbury, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Replimune

Replimune is creating a new class of oncolytic immunotherapy designed to ignite a powerful immune response to treat cancer and vaccinate against future relapse. Replimune`s mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response. Replimune is pioneering the development of novel tumor-directed oncolytic immunotherapies. We imagine a world where cancer is a curable disease.

Eidos Therapeutics

Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis.